International Journal of Applied Sciences: Current and Future Research Trends
Hiwa Khalid Qadir, Hama Nejm Jaff, Hemin Khalid Saber
Background and objectives: Favipiravir (FAV) is considered to have potential efficacy against the SARS-CoV-2 virus. We aimed to explore the efficacy of favipiravir in the treatment of mild and moderate cases of COVID-19 pneumonia. Methods: 250 patients of mild and moderate COVID-19 patients confirmed by reverse transcription-polymerase chain reaction (RT-PCR) were included from 22 nd of June 2020 till 25 th of October 2021, aged 18 to 90 years, 125 patients received FAV 3200 mg no day 1 followed by 600 mg twice daily (from day 2 -day 10). In another group, 125 patients did not receive favipiravir (SOC, standard of care group). They received paracetamol, vitamins D, and C plus Zinc, and azithromycin within the first 10 days of symptoms' onset. In both groups, the patients were monitored for clinical recovery on the 5 th ,10 th, 15 th days and after one month of receiving the therapeutic trials. Patients were enrolled from Rizgari Teaching Hospital, and from an outpatient respiratory private clinic. Both arms were comparable as regards demographic characteristics, severity, and comorbidities. It was a non-randomized -controlled trial. Results: On day five, the rate of clinical improvement in the FAV group (74.4%) was significantly (p < 0.001) higher than the rate in the SOC group (12.8%). On day 10, the mentioned rate was 88.8% in the FAV group compared with 47.2% in the SOC group (p < 0.001). The median time of clinical recovery was 6.5 days in the FAV group vs.
References
Abdulah, Qazli, Suleman, Response of the Public to Preventive Measures of COVID-19 in Iraqi Kurdistan, Disaster Med Public Health Prep,
doi:10.1017/dmp.2020.233Bhagat, Vora, Daxini, Dadhich, Patil et al., Clinical usefulness of favipiravir in moderate COVID-19 patients: Indian real-world experience, Indian Journal of Critical Care Medicine
Cai, Yang, Liu, Chen, Shu et al., treatment with favipiravir for COVID-19: an open-label control study, Experimental International Journal of Applied Sciences: Current and Future Research Trends (IJASCFRT)
Dabbous, El-Sayed, Assal, Elghazaly, Ebeid et al., Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial, Scientific reports
Furuta, Komeno, Nakamura, Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase, Proceedings of the Japan Academy, Series B
Hayden, Shindo, Influenza virus polymerase inhibitors in clinical development. Current opinion in infectious diseases
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, The lancet
Ivashchenko, Dmitriev, Vostokova, Azarova, Blinow et al., AVIFAVIR for treatment of patients with moderate COVID-19: interim results of a phase II/III multicenter randomized clinical trial, medRxiv
Liu, Chang, Wang, Tsai, Hung et al., Prolonged virus shedding even after seroconversion in a patient with COVID-19, J Infect
Madelain, Oestereich, Graw, Nguyen, De Lamballerie et al., Ebola virus dynamics in mice treated with favipiravir, Antiviral research
Ruzhentsova, Oseshnyuk, Soluyanova, Dmitrikova, Mustafaev et al., Phase 3 trial of coronavir (favipiravir) in patients with mild to moderate COVID-19, American Journal of Translational Research
Udwadia, Singh, Barkate, Patil, Rangwala et al., Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial, International Journal of Infectious Diseases
Zhonghua, He, Hu, Za, Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia, Bibl. Nac. Med
